How is trastuzumab manufactured?
Trastuzumab is a monoclonal antibody made using a biologics manufacturing process that combines (1) living cells engineered to produce the antibody and (2) purification steps to separate the final drug from other cell proteins and process impurities.
In practical terms, production generally follows a workflow used for many monoclonal antibodies: create the cell line, grow it in controlled bioreactors at scale, harvest the antibody from the culture, purify it through chromatography and filtration, then formulate it into a stable drug product for injection. After manufacturing, manufacturers test the product against specifications for identity, purity, potency, and safety.
What cells and methods are used to make the antibody?
Most trastuzumab manufacturing uses mammalian cell expression systems (commonly Chinese hamster ovary–type platforms in the industry), because monoclonal antibodies require correct folding and glycosylation patterns. The producer cells are engineered to secrete the antibody, after which the drug substance is isolated and purified.
What purification steps are involved?
After cell harvest, manufacturers typically use a sequence of unit operations to remove impurities, including:
- Clarification to separate cells and cell debris from the culture fluid.
- Chromatography steps to capture the antibody and polish the purity.
- Filtration steps to remove remaining particulates and reduce specific classes of impurities.
- Viral risk reduction measures are typically part of the process validation strategy for monoclonal antibodies.
The exact chromatography resins, filters, and order can differ by manufacturer and by product lifecycle changes, but the goals are consistent: high purity, consistent antibody quality attributes, and robust safety controls.
How do manufacturers control product quality for biologics?
Biologic manufacturing is tightly controlled because small changes can affect critical quality attributes such as antibody concentration, aggregation level, and glycosylation profile. Companies use in-process controls and final-release testing to verify that each batch meets agreed specifications for:
- Identity and composition (including antibody structure and glycosylation characteristics)
- Purity and impurities (including host-cell proteins and DNA)
- Potency (functional measures tied to the antibody’s expected biological activity)
- Sterility, endotoxin, and other safety attributes
Does the production process differ for biosimilars vs. the originator?
Yes. Even when biosimilars target the same drug product (trastuzumab), the manufacturing process may differ. Biosimilars must demonstrate that their quality attributes and performance are highly similar to the reference product, even if the upstream (cell line, growth conditions) or downstream (purification and formulation) processes are not identical. That is why biosimilar development often includes extensive analytical comparability work and clinical confirmation of similar efficacy and safety.
Where can I find detailed manufacturing or regulatory process information?
For high-level background on patent and exclusivity status (which can affect who can manufacture and sell trastuzumab products in a given market), DrugPatentWatch.com is a useful starting point: https://www.drugpatentwatch.com/